Preinvasive immune-cell network offers a research route to lung cancer interception
Published in Biology, Drugs development & discovery, Immunology, Journals.
October 8, 2026 — A study published in Nature on October 7 identifies a regulatory T-cell network that could help researchers track lung cancer development before invasive disease.
Samuel Gamble, Zoe E. Whiteman and colleagues profiled immune cells across tissues in patients undergoing surveillance of preinvasive lung lesions. BATF-expressing effector regulatory T cells accumulated in high-grade airway lesions and shared cellular lineages with counterparts in blood. Rising circulating levels accompanied preinvasive progression; the network was also associated with rapid progression in early-stage non-small-cell lung cancer.
In carcinogen-exposed mice, inhibiting PI3Kδ disrupted regulatory-T-cell-rich immature lymphoid structures, reduced these cells in blood and lungs, increased local conventional type 1 dendritic cells, and reduced lung tumour incidence and size.
The treatment findings are preclinical. Human observations support further investigation of biomarkers, but do not establish an approved blood-screening test or demonstrate that PI3Kδ inhibition prevents cancer in people. Clinical validation and safety studies would be needed before such an interception strategy could enter routine care.
Source: Gamble et al., Nature, published October 7, 2026. DOI: 10.1038/s41586-026-11066-6.